IRRITABLE BOWEL SYNDROME AND MICROBIOTA: THERAPY OPTIMIZATION WAYS

Download full text PDF
Issue: 
5
Year: 
2015

Professor M. Osadchuk (1), MD; M. Osadchuk (2), Candidate of Medical Sciences 1 -I.M. Sechenov First Moscow State Medical University 2 -City Polyclinic Fifty-Two, Moscow Healthcare Department

The paper provides an analytical review of the role of the intestinal microflora in developing irritable bowel syndrome (IBS). There is no doubt that the intestinal microflora may initiate the symptoms of IBS, by altering intestinal neuromotor, sensory, and barrier functions and their interaction along the gutbrain axis.
Keywords: 
irritable bowel syndrome
microbiota
probiotics
Linex

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Zaharenko S.M. Antibiotiki i probiotiki: konkurenty ili sinergisty? // Epidem. i infektsion. bol. – 2007; 5 (1): 47–53.
  2. Osadchuk M.A., Svistunov A.A.. Antibiotikoassotsiirovannaja diareja v kliniches-koj praktike // Vopr. sovrem. pediatrii. – 2014; 13 (1); 102–8.
  3. Parfenov A.I., Ruchkina I.N., Ataullahanov R.I. Postinfektsionnyj sindrom razdrazhennogo kishechnika. Osobennosti patogeneza, diagnostiki i lechenija // Rus. med. zhurn. – 2009; 11 (2): 1–5.
  4. Amaral F., Sachs D., Costa V. et al. Commensal microbiota is fundamental for the development of inflammatory pain // Proc. Natl. Acad. Sci. USA. – 2008; 105: 2193–7.
  5. Asano Y., Hiramoto T., Nishino R. et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice // Am. J. Physiol. Gastrointest. Liver Physiol. – 2012; 303: 1288–95.
  6. Lyte M. Microbial endocrinology and infectious disease in the 21st century // Trends Microbiol. – 2004; 12: 14–20.
  7. Belmonte L., Beutheu-Youmba S., Bertiaux-Vanda ële N. et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype // PLoS One. – 2012; 7: 42777.
  8. Bindels L., Dewulf E., Delzenne N. GPR43/FFA2: physiopathological relevance and therapeutic prospects // Trends Pharmacol. Sci. – 2013; 34: 226–32.
  9. Bouhnik Y., Alain S., Attar A. et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome // Am. J. Gastroenterol. – 1999; 94: 1327–31.
  10. Buhner S., Li Q., Vignali S. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome // Gastroenterology. – 2009; 137: 1425–34.
  11. Carroll I., Ringel-Kulka T., Siddle J. et al. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage // PLoS One. – 2012; 7: 46953.
  12. Chalmers N., Palmer R., Cisar J. et al. Characterization of a Streptococcus spr. – Veillonella spr. community micromanipulated from dental plaque // J. Bacteriol. – 2008; 190: 8145–54.
  13. Cogan T., Thomas A., Rees L. et al. Norepinephrine increases the pathogenic potential of Campylobacter jejuni // Gut. – 2007; 56: 1060–5.
  14. Faith J., Guruge J., Charbonneau M. et al. The long-term stability of the human gut microbiota // Science. – 2013; 341: 1237439.
  15. Fukudo S. Pathogenesis of irritable bowel syndrome // Nihon Shokakibyo Gakkai Zasshi. – 2014; 111 (7): 1323–33
  16. Guglielmetti S., Mora D., Gschwender M. et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study // Aliment. Pharmacol. Ther. – 2011; 33: 1123–32.
  17. Ivanov D., Emonet C., Foata F. et al. A serpin from the gut bacterium Bifidobacteriumlongum inhibits eukaryotic elastase-like serine proteases // J. Biol. Chem. – 2006; 281: 17246–52.
  18. Jeffery I., O’Toole P., 18. Öhman L. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota // Gut. – 2012; 61: 997–1006.
  19. Lekha Saha. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine // World J. Gastroenterol. – 2014; 20 (22): 6759–73.
  20. Liebregts T., Adam B., Bredack C. et al. Immune activation in patients with irritable bowel syndrome. Immune activation in patients with irritable bowel syndrome // Gastroenterology. – 2007; 132: 913–20.
  21. Lyra A., Rinttil21. ä T., Nikkilä J. et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification // World J. Gastroenterol. – 2009; 15: 5936–45.
  22. Lyte M. Microbial endocrinology and infectious disease in the 21st century . // Trends Microbiol. – 2004; 12: 14–20
  23. Lyte M., Freestone P. Microbial Endocrinology: interkingdom signaling in health and disease. Springer Publishers; 2010.
  24. Macfarlane G., Allison C., Gibson S. et al. Contribution of the microflora to . proteolysis in the human large intestine // J. Appl. Bacteriol. – 1988; 64: 37–46.
  25. Macfarlane S., Woodmansey E., Macfarlane G. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system // Appl. Environ. Microbiol. – 2005; 71: 7483–92.
  26. Malinen E., Rinttil26. ä T., Kajander K. et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR // Am. J. Gastroenterol. – 2005; 100: 373–82.
  27. Matricon J., Meleine M., Gelot A. et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome // Aliment. Pharmacol. Ther. – 2012; 36: 1009–31.
  28. Milani C., Hevia A., Foroni E. et al. Assessing the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol // PLoS One. – 2013; 8 (7): 68739
  29. Nam Y., Jung M., Roh S. et al. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing // PLoS One. – 2011; 6: 22109.
  30. Nohr M., Pedersen M., Gille A. et al. GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes // Endocrinology. – 2013; 154: 3552
  31. Paliy O., Kenche H., Abernathy F. et al. High-throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray // Appl. Environ. Microbiol. – 2009; 75: 3572–9.
  32. Parkes G., Sanderson J., Whelan K. Treating irritable bowel syndrome with probiotics: the evidence // Proc. Nutr. Soc. – 2010; 69: 187–94.
  33. Parkes G., Rayment N., Hudspith B. et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome // Neurogastroenterol. Motil. – 2012; 24: 31–9.
  34. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing // Nature. – 2010; 464: 59–65.
  35. Quigley E., Craig O. Irritable bowel syndrome; update on pathophysiology and management // Turk. J. Gastroenterol. – 2012; 23 (4): 313–22.
  36. Rajili36. -Stojanovi M., Biagi E., Heilig H. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome // Gastroenterology. – 2011; 141: 1792–801.
  37. Rajili37. -Stojanovi M. Diversity of the Human Gastrointestinal Microbiota-Novel Perspectives from High Throughput Analyses [PhD thesis] / Wageningen: Wageningen University, 2007.
  38. Rigsbee L., Agans R., Shankar V. et al. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome // Am. J. Gastroenterol. – 2012; 107 (11): 1740–51.
  39. Sanders M., Guarner F., Guerrant R. et al. An update on the use and investigation of probiotics in health and disease // Gut. – 2013; 62: 787–96.
  40. Santos J., Saperas E., Nogueiras C. et al. Release of mast cell mediators into the jejunum by cold pain stress in humans // Gastroenterology. – 1998; 114: 640–8.
  41. Simr41. én M., Barbara G., Flint H. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report // Gut. – 2013; 62 (1): 159–76.
  42. Sommer F., Bäckhed F. The gut microbiota--masters of host development and physiology // Nat. Rev. Microbiol. – 2013; 11: 227–38.
  43. Spiegel B. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective // Clin. Gastroenterol. Hepatol. – 2011; 9: 461–9.
  44. Spiller R., Garsed K. Postinfectious irritable bowel syndrome // Gastroenterology. – 2009; 136: 1979–88.
  45. Tana C., Umesaki Y., Imaoka A. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome // Neurogastroenterol. Motil. – 2010; 22: 512–9, e114–5.
  46. Thompson W., Longstreth G., Drossman D. et al. Functional bowel disorders and functional abdominal pain // Gut. – 1999; 45 (Suppl. 2): 43–7.
  47. Saulnier D., Riehle K., Mistretta T. et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome // Gastroenterology. – 2011; 141: 1782–91.
  48. Wilson S., Roberts L., Roalfe A. et al. Prevalence of irritable bowel syndrome: a community survey // Br. J. Gen. Pract. – 2004; 54: 495–502.
  49. Yang H., Stephens R., Tache Y. TRH analogue microinjected into specific medullary nuclei stimulates gastric serotonin secretion in rats // Am. J. Physiol. – 1992; 262(2 Pt 1): 216–22.
  50. Suhorukova M.V., Timohova A.V., Ejdel'shtejn M.V. i dr. Chuvstvitel'nost' k antibiotikam shtammov bakterij, vhodjaschih v sostav pro-biotika Lineks® // Klin. mikrobiol. i antimikrob. himioter. – 2012; 14 (3): 248–51.